Page 5,579«..1020..5,5785,5795,5805,581..5,5905,600..»

Fighting Parkinson ‘s with exercise

Posted: Published on March 14th, 2013

John Hougan was 52 when he was diagnosed with Parkinson's disease. What began as a slight tremor one morning soon led him to Vancouver General Hospital. After three days of tests, he received the news. "I was taken aback," he said of the diagnosis. "It's not something that's in my family. At first, I was more bothered by not knowing what it was. I knew a little bit about Parkinson's because my wife works with somebody who has it." He also was aware that actor Michael J. Fox has the disease. "The first thing you think is: how fast is this going to progress?" Caused by a decrease in the production of dopamine, Parkinson's is characterized by uncontrollable movements and muscular rigidity. It usually strikes adults over 50, although the degenerative disease can hit earlier, particularly when there is a family history of Parkinson's. The average age of diagnosis in Canada is approximately 62, but Parkinson Society Canada says there has been an increase in the number of patients under the age of 50. There is no known cure for the disease. Current treatments call for medication that includes synthetic dopamine. But Hougan, an active person to begin with, has … Continue reading

Posted in Parkinson's Treatment | Comments Off on Fighting Parkinson ‘s with exercise

Acorda to Present New Research on Novel Multiple Sclerosis and Epilepsy Therapies at American Academy of Neurology …

Posted: Published on March 14th, 2013

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc.(Nasdaq:ACOR) will present new research data at the 65th American Academy of Neurology Annual Meeting on AMPYRA(dalfampridine) Extended Release Tablets, 10 mg, an FDA-approved therapy indicated to improve walking in people with multiple sclerosis, and Diazepam Nasal Spray, an investigational therapy for the treatment of cluster seizures, also known as acute repetitive seizures, in people with epilepsy. Acorda is focused on improving the lives of people with neurological disorders. We currently are developing seven therapies for a range of conditions, including multiple sclerosis, epilepsy and spinal cord injury, saidRon Cohen, M.D., Acorda Therapeutics President and CEO. Our presentations at AAN include new studies on AMPYRA and the first clinical data presented on Diazepam Nasal Spray. These studies have increased our understanding of the potential roles these therapies could have in addressing the urgent needs of patients with these conditions. Data being presented on Acorda-developed therapies at the AAN annual meeting include: More detailed information on scientific sessions and data presentations at the AAN annual meeting can be found on the conference website (http://www.aan.com/go/am13). Important Safety Information Do not take AMPYRA if you have ever had a seizure or have certain types of kidney problems. Take … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on Acorda to Present New Research on Novel Multiple Sclerosis and Epilepsy Therapies at American Academy of Neurology …

Cord blood gives families hope

Posted: Published on March 14th, 2013

When a baby is born, medical professionals routinely throw away a sick child's potential lifeline. Dr. Hugh Miller of Obstetrix Medical Group, 5301 E. Grant Road, is working to establish the upside of storing umbilical cord blood, which contains stem cells that doctors may someday be able to use to heal a variety of medical conditions. Miller, Cord Blood Registry and the Save the Cord Foundation created the Newborn Possibilities Program. Cord Blood Registry processes and stores cord blood stem cells, for babies born after high-risk deliveries, for use in future treatments. Miller chose participants by establishing an algorithm to identify pregnant mothers whose fetuses were at risk of developing cerebral palsy and other neurological problems. Between 2009 and 2011, the program selected 1,200 babies. Cord Blood Registry pays for the cord blood collection, processing and storage in the registry's stem cell processing and storage facility. Costs can be prohibitive for parents who want to store cord blood. Banking costs about $2,000 initially, then between $100 and $200 a year. Marana resident Jessica Schaefer, whose 2-year-old son, Logan, is participating in the study, is eager to discover the treatment's potential. A subsequent study has been crucial for Schaefer, a 36-year-old … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on Cord blood gives families hope

Cerebral Palsy Family Network Launches Community Support Forum

Posted: Published on March 14th, 2013

The Cerebral Palsy Family Network has launched an online forum for parents of children with cerebral palsy to have conversations and share ideas to better the lives of their children. Austin, TX (PRWEB) March 14, 2013 The new online forum compliments our website and active social media presence, allowing community members to maintain ongoing discussions about raising a child with cerebral palsy, said Lee Vander Loop, CP Family Network Editor. We hope parents and caregivers will use the forum to share tips, ask questions, and provide support and encouragement to other parents, added Vander Loop. To participate in the discussion, visit cpfamilynetwork.org and click on the forum link on the home page. Before posting a question or comment, community members will need to create an account and check their email for a temporary password. Further instructions are available upon log-in. Once registered, members can contribute to existing conversations or start their own topics. Cerebral Palsy Family Network The Cerebral Palsy Family Network is a 501-C3 non-profit organization whose mission is to provide medical and legal resources to families and children with cerebral palsy. Among the resources it offers parents are the Cerebral Palsy Online Resource Directory, a free searchable database … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on Cerebral Palsy Family Network Launches Community Support Forum

Traumatic Brain Injury ¦ Treatment and Symptoms – Video

Posted: Published on March 14th, 2013

Traumatic Brain Injury Treatment and Symptoms XXXXXX◅ Traumatic Brain Injury treatment mdash; Finding the right information about Traumatic Brain Injury treatment symptoms, is crucial to managing Traumatic... By: MainMDcom … Continue reading

Posted in Brain Injury Treatment | Comments Off on Traumatic Brain Injury ¦ Treatment and Symptoms – Video

Brain injuries to be researched

Posted: Published on March 14th, 2013

The US National Football League has joined GE, a world leader in medical imaging, in launching a $US60 million ($A59.07 million) research program aimed at improving diagnosis and treatment of traumatic brain injuries. The four-year Head Health Initiative, guided by healthcare experts, aims to improve athlete concussion safety with innovations that could be used by soldiers as well as in society. Part of the program in conjunction with sportswear maker Under Armour includes an innovation challenge program to start late this year with investments of up to $20 million for research and technology to better understand, diagnose and protect against brain injuries. 'Our knowledge of the brain is far behind that of nearly every other organ,' GE chairman Jeff Immelt said. 'With this initiative, we will advance our research and apply our learning to sports-related concussions, brain injuries suffered by members of the military and neurodegenerative diseases.' The NFL has worked to reduce concussions and their impact on players by tougher penalties for blows to the head and mandatory evaluations before those hurt can return to the field after complaints from present and former players. 'The NFL has made tremendous progress in making the game safer and more exciting. But … Continue reading

Posted in Brain Injury Treatment | Comments Off on Brain injuries to be researched

Brookhaven Retreat Participates in Brain Injury Awareness Month

Posted: Published on March 14th, 2013

Brookhaven Retreat, a unique residential treatment facility exclusively for women with mental health and/or substance abuse issues, helps women recover from the damage caused by posttraumatic stress disorder. Knoxville, TN (PRWEB) March 13, 2013 Emotional trauma changes the brains chemistry from the inside, altering a womans response to stress. An article published in Dialogues in Clinical Neuroscience states that trauma alters the long-term functioning of the prefrontal cortex, amygdala and hippocampus, areas associated with decision making, memories and emotional reactions. Traumatic memories are stored in the more primitive, subcortical regions of the brain where they are not accessible by the reasoning areas. When stored here, it takes very little sensory stimulation to trigger the memory and create a perceived sense of threat in the brain. Women who suffer from a psychologically traumatic event can develop posttraumatic stress disorder, which is characterized by flashbacks, nightmares, problems sleeping, irritability and hypervigilance that negatively affects day-to-day life. The event that triggers the disorder is subjective; bullying and humiliation can cause trauma for some and not for others. Women suffering from PTSD organize their lives around warding off traumatic memories and reliving the trauma. The injury affects every aspect of life, directing where they … Continue reading

Posted in Brain Injury Treatment | Comments Off on Brookhaven Retreat Participates in Brain Injury Awareness Month

Low cognitive score and risk of brain injury linked

Posted: Published on March 14th, 2013

Mar. 12, 2013 Young men with low cognitive function and low socioeconomic status are significantly more likely to suffer from mild traumatic brain injury than those without, a new study suggests. It is estimated that there are 10 million cases of traumatic brain injury globally every year with mild traumatic brain injuries being responsible for 70-90% of these. Incidence is highest among young males. Current literature suggests that mild traumatic brain injuries cause changes in brain tissues and have important long-term consequences on cognitive function. Deficits have been described in attention, memory, verbal learning and processing speed and may occur in 15-25% of those suffering one of these injuries. However, little is known about population-wide cognitive function before a mild traumatic brain injury and whether low cognitive function is a risk factor. Researchers from Umea University in Sweden therefore carried out a nationwide study on over 300,000 young men who were conscripted for military service in Sweden between 1989 and 1994, all of whom took part in a cognitive test. Average follow-up was 19 years. The main outcome was mild traumatic brain injuries in relation to cognitive function and other potential risk factors. Information on diagnosis of mild traumatic brain … Continue reading

Posted in Brain Injury Treatment | Comments Off on Low cognitive score and risk of brain injury linked

MS – Video

Posted: Published on March 14th, 2013

MS Help support MS awareness. By: Megan Komp … Continue reading

Posted in MS Treatment | Comments Off on MS – Video

Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every …

Posted: Published on March 14th, 2013

Basel, March 13, 2013 - New data will be presented at the 65th annual meeting of the American Academy of Neurology (AAN) that show continued innovation within the Novartis Multiple Sclerosis (MS) portfolio[1]. Growing clinical trial and real-world experience with Gilenya (fingolimod), the first once-daily oral therapy approved to treat people with relapsing MS (RMS),will be highlighted[2-7]. Updates on studies of Gilenya in people with primary-progressive MS (PPMS)[8] and the investigational agent BAF312 (siponimod) in people with secondary-progressive MS (SPMS) will also be communicated[9]. "Novartis is pleased to present new data that underscore Gilenya`s pioneering role in the treatment of MS," said Dr. Timothy Wright, Global Head Development, Novartis Pharmaceuticals AG. "These results, as well as updates on our investigational MS compound BAF312 (siponimod) show that we are making real progress in our commitment to address unmet medical need in MS and to provide a treatment at every stage of the disease." Data from three large Phase III studies will highlight the efficacy of Gilenya in reducing the rate of brain volume loss[2], the best characterized magnetic resonance imaging (MRI) predictor of long-term disability. There will also be a presentation on the INFORMS study, which is evaluating Gilenya in patients … Continue reading

Posted in MS Treatment | Comments Off on Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every …

Page 5,579«..1020..5,5785,5795,5805,581..5,5905,600..»